{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:47:30Z","timestamp":1791488850718,"version":"4.3.4"},"reference-count":139,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atherosclerotic cardiovascular diseases (ASCVD) are the major cause of mortality worldwide. Despite the continuous progress in ASCVD therapy, the residual risk persists beyond the management of traditional risk factors. Several infections including Helicobacter pylori infection, periodontal disease, and viral infections are associated with the increased risk of ASCVD, both directly by damage to the heart muscle and vasculature, and indirectly by triggering a systemic proinflammatory state. Hence, beyond the optimal management of the traditional ASCVD risk factors, infections should be considered as an important non-classical risk factor to enable early diagnosis and appropriate treatment. Here, we summarized the currently available evidence regarding the role of inflammation in ASCVD and the association between the particular infections and pathogens (Helicobacter pylori, periodontal disease, pneumonia, Cytomegalovirus, Human immunodeficiency virus, Herpes simplex virus, and severe acute respiratory syndrome coronavirus 2) on the development and progression of ASCVD. We also speculated about the potential therapeutic implications of the anti-inflammatory and anti-infective drugs on ASCVD outcomes, including drugs routinely administered in patients with ASCVD (statins, P2Y12 receptor inhibitors, and angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers) and novel strategies aiming at residual risk reduction (colchicine, anti-cytokine drugs, and methotrexate). Considering the emerging association between infections and ASCVD, it is crucial to determine the possible advantages of infection prevention and treatment in patients with ASCVD.<\/jats:p>","DOI":"10.3390\/jcm10122539","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T12:08:55Z","timestamp":1623154135000},"page":"2539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6835-9720","authenticated-orcid":false,"given":"Piotr","family":"Szwed","sequence":"first","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-7587","authenticated-orcid":false,"given":"Aleksandra","family":"G\u0105secka","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Zawadka","sequence":"additional","affiliation":[{"name":"2nd Department of Anaestesiology and Intensive Therapy, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3324-9625","authenticated-orcid":false,"given":"Ceren","family":"Eyileten","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4458","authenticated-orcid":false,"given":"Marek","family":"Postu\u0142a","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-8741","authenticated-orcid":false,"given":"Tomasz","family":"Mazurek","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-5455","authenticated-orcid":false,"given":"\u0141ukasz","family":"Szarpak","sequence":"additional","affiliation":[{"name":"Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy in Warsaw, 03-411 Warsaw, Poland"},{"name":"Maria Sklodowska-Curie Bialystok Oncology Center, 02-034 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-0877","authenticated-orcid":false,"given":"Krzysztof J.","family":"Filipiak","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"ref_1","unstructured":"(2021, March 20). WHO Data. Available online: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases#tab=tab_1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/2047487319869400","article-title":"Lifestyle Factors and High-Risk Atherosclerosis: Pathways and Mechanisms beyond Traditional Risk Factors","volume":"27","author":"Lechner","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/00015458.2005.11679782","article-title":"Role of Inflammation and Infection in Vascular Disease","volume":"105","author":"Corrado","year":"2005","journal-title":"Acta Chir. Belg."},{"key":"ref_6","first-page":"116","article-title":"Bin. Basic Pathogenic Mechanisms of Atherosclerosis","volume":"7","author":"Alfarisi","year":"2020","journal-title":"Egypt. J. Basic Appl. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Davignon, J., and Ganz, P. (2004). Role of Endothelial Dysfunction in Atherosclerosis. Circulation, 109.","DOI":"10.1161\/01.CIR.0000131515.03336.f8"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.3402\/jom.v2i0.5781","article-title":"Cardiovascular Disease and the Role of Oral Bacteria","volume":"2","author":"Leishman","year":"2010","journal-title":"J. Oral Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s10096-017-3054-0","article-title":"Helicobacter Pylori Infection and Atherosclerosis: Is There a Causal Relationship?","volume":"36","author":"Xu","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_10","first-page":"1437","article-title":"Cytomegalovirus Infection in Cardiovascular Diseases","volume":"83","author":"Lebedeva","year":"2018","journal-title":"Biochemistry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/resp.13233","article-title":"Pneumonia as a Cardiovascular Disease","volume":"23","author":"Restrepo","year":"2018","journal-title":"Respirology"},{"key":"ref_12","first-page":"72","article-title":"Contribution of Common Infections to Cardiovascular Risk in HIV-Positive Individuals","volume":"19","author":"Berquist","year":"2017","journal-title":"AIDS Rev."},{"key":"ref_13","first-page":"2630865","article-title":"Herpes Simplex Virus Type 1 and Type 2 Infection Increases Atherosclerosis Risk: Evidence Based on a Meta-Analysis","volume":"2016","author":"Wu","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.hlc.2020.05.101","article-title":"SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart","volume":"29","author":"Dhakal","year":"2020","journal-title":"Heart Lung Circ."},{"key":"ref_15","unstructured":"(2021, May 02). WHO Data. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.ATV.15.5.551","article-title":"The Response-to-Retention Hypothesis of Early Atherogenesis","volume":"15","author":"Williams","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The Immune System in Atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11883-014-0435-z","article-title":"Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target","volume":"16","author":"Golia","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacc.2006.08.011","article-title":"Inflammation and Atherothrombosis. From Population Biology and Bench Research to Clinical Practice","volume":"48","author":"Libby","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/HCO.0000000000000625","article-title":"New Evidence on the Role of Inflammation in CVD Risk","volume":"34","author":"Lorenzatti","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","article-title":"Role of Inflammation in the Pathogenesis of Atherosclerosis and Therapeutic Interventions","volume":"276","author":"Raggi","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_22","first-page":"18","article-title":"Transforming Growth Factor-\u03b2 Signaling in T Cells Promotes Stabilization of Atherosclerotic Plaques through an Interleukin-17-Dependent Pathway","volume":"5","author":"Robertson","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2017.10.081","article-title":"Taming Immune and Inflammatory Responses to Treat Atherosclerosis","volume":"71","author":"Libby","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100694","DOI":"10.1016\/j.blre.2020.100694","article-title":"Platelet Activation and Prothrombotic Mediators at the Nexus of Inflammation and Atherosclerosis: Potential Role of Antiplatelet Agents","volume":"45","author":"Lordan","year":"2021","journal-title":"Blood Rev."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"G\u0105secka, A., Rogula, S., Szarpak, \u0141., and Filipiak, K.J. (2021). LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis. Life, 11.","DOI":"10.3390\/life11010039"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kelley, N., Jeltema, D., Duan, Y., and He, Y. (2019). The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133328"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/CIRCRESAHA.120.316710","article-title":"Atrial Myocyte NLRP3\/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation","volume":"127","author":"Heijman","year":"2020","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/pr.112.005983","article-title":"Classification, Functions, and Clinical Relevance of Extracellular Vesicles","volume":"64","author":"Harrison","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.metabol.2018.04.008","article-title":"Extracellular Vesicles Characteristics and Emerging Roles in Atherosclerotic Cardiovascular Disease","volume":"85","author":"Hafiane","year":"2018","journal-title":"Metabolism"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"G\u0105secka, A., Pluta, K., Solarska, K., Rydz, B., Eyileten, C., Postula, M., Van Der Pol, E., Nieuwland, R., Budnik, M., and Kochanowski, J. (2021). Plasma Concentrations of Extracellular Vesicles Are Decreased in Patients with Post-Infarct Cardiac Remodelling. Biology, 10.","DOI":"10.3390\/biology10020097"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5603\/KP.a2017.0178","article-title":"Extracellular Vesicles in Post-Infarct Ventricular Remodelling","volume":"76","author":"Nieuwland","year":"2018","journal-title":"Kardiol. Pol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gasecka, A., Nieuwland, R., and Siljander, P.R.M. (2019). Platelet-Derived Extracellular Vesicles. Platelets, Academic Press. [4th ed.].","DOI":"10.1016\/B978-0-12-813456-6.00022-9"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.17219\/acem\/62915","article-title":"MicroRNA in Cardiovascular Biology and Disease","volume":"26","author":"Wojciechowska","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1599-9","article-title":"MicroRNA-181a-5p and MicroRNA-181a-3p Cooperatively Restrict Vascular Inflammation and Atherosclerosis","volume":"10","author":"Su","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_35","first-page":"100","article-title":"MicroRNA-30c Reduces Hyperlipidemia and Atherosclerosis by Decreasing Lipid Synthesis and Lipoprotein Secretion","volume":"176","author":"Soh","year":"2016","journal-title":"Physiol. Behav."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3487","article-title":"MicroRNA-126-5p Promotes Endothelial Proliferation and Limits Atherosclerosis by Suppressing Dlk1","volume":"20","author":"Schober","year":"2014","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.atherosclerosis.2014.07.005","article-title":"MicroRNA-19b Promotes Macrophage Cholesterol Accumulation and Aortic Atherosclerosis by Targeting ATP-Binding Cassette Transporter A1","volume":"236","author":"Lv","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/ATVBAHA.116.308916","article-title":"Microrna-33 regulates macrophage autophagy in atherosclerosis","volume":"37","author":"Ouimet","year":"2017","journal-title":"Arterioscler. Thrombo. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCRESAHA.114.302213","article-title":"Inhibition of MicroRNA-92a Prevents Endothelial Dysfunction and Atherosclerosis in Mice","volume":"114","author":"Loyer","year":"2014","journal-title":"Circ. Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hu, Y.W., Hu, Y.R., Zhao, J.Y., Li, S.F., Ma, X., Wu, S.G., Lu, J.B., Qiu, Y.R., Sha, Y.H., and Wang, Y.C. (2014). An Agomir of MiR-144-3p Accelerates Plaque Formation through Impairing Reverse Cholesterol Transport and Promoting pro-Inflammatory Cytokine Production. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094997"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1172\/JCI61716","article-title":"MicroRNA-155 Promotes Atherosclerosis by Repressing Bcl6 in Macrophages","volume":"122","author":"Wei","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/CIRCULATIONAHA.112.000736","article-title":"The MicroRNA-342-5p Fosters Inflammatory Macrophage Activation through an Akt1- and MicroRNA-155-Dependent Pathway during Atherosclerosis","volume":"127","author":"Wei","year":"2013","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.vph.2018.11.006","article-title":"The Function of MiR-143, MiR-145 and the MiR-143 Host Gene in Cardiovascular Development and Disease","volume":"112","author":"Vacante","year":"2019","journal-title":"Vascul. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gozdowska, R., Makowska, A., G\u0105secka, A., Chabior, A., and Marchel, M. (2020). Circulating MicroRNA in Heart Failure\u2014Practical Guidebook to Clinical Application. Cardiol Rev.","DOI":"10.1097\/CRD.0000000000000352"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.5603\/KP.2018.0118","article-title":"Dysregulations of MiRNAs and Galectin-3 May Underlie Left Ventricular Dilatation in Patients with Systolic Heart Failure","volume":"76","author":"Tomaniak","year":"2018","journal-title":"Kardiol. Pol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Arida, A., Protogerou, A.D., Kitas, G.D., and Sfikakis, P.P. (2018). Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071890"},{"key":"ref_47","first-page":"460","article-title":"Rheumatoid Arthritis and Atherosclerosis","volume":"21","author":"Adawi","year":"2019","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Liccardo, D., Cannavo, A., Spagnuolo, G., Ferrara, N., Cittadini, A., Rengo, C., and Rengo, G. (2019). Periodontal Disease: A Risk Factor for Diabetes and Cardiovascular Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061414"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.micpath.2013.04.006","article-title":"Prevalence of Aggregatibacter Actinomycetemcomitans, Porphyromonas Gingivalis and Tannerella Forsythia in Japanese Patients with Generalized Chronic and Aggressive Periodontitis","volume":"61","author":"Tomita","year":"2013","journal-title":"Microb. Pathog."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cre2.336","article-title":"Risk of Incident Cardiovascular Disease in People with Periodontal Disease: A Systematic Review and Meta-Analysis","volume":"7","author":"Larvin","year":"2021","journal-title":"Clin. Exp. Dent. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.hlc.2018.05.102","article-title":"Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular Disease","volume":"27","year":"2018","journal-title":"Heart Lung Circ."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/jcpe.13189","article-title":"Periodontitis and Cardiovascular Diseases: Consensus Report","volume":"47","author":"Sanz","year":"2020","journal-title":"J. Clin. Periodontol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1111\/jcpe.12060","article-title":"Inflammatory Mechanisms Linking Periodontal Diseases to Cardiovascular Diseases","volume":"40","author":"Schenkein","year":"2013","journal-title":"J. Clin. Periodontol."},{"key":"ref_54","first-page":"E681","article-title":"Periodontal Treatment on Patients with Cardiovascular Disease: Systematic Review and Meta-Analysis","volume":"23","year":"2018","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2019.08.012","article-title":"Treating Periodontal Disease in Patients with Myocardial Infarction: A Randomized Clinical Trial","volume":"71","author":"Lobo","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_56","first-page":"353","article-title":"Treatment of Periodontitis and Endothelial Function","volume":"67","author":"Tonetti","year":"2008","journal-title":"Jpn. J. Chest Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105511","DOI":"10.1016\/j.phrs.2021.105511","article-title":"Periodontal Therapy and Treatment of Hypertensio\u2014Alternative to the Pharmacological Approach. A Systematic Review and Meta-Analysis","volume":"19","author":"Sharma","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1600-051X.2006.00931.x","article-title":"C-Reactive Protein in Patients with Coexistent Periodontal Disease and Acute Coronary Syndromes","volume":"33","author":"Czerniuk","year":"2006","journal-title":"J. Clin. Periodontol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11906-021-01140-x","article-title":"Periodontitis, Blood Pressure, and the Risk and Control of Arterial Hypertension: Epidemiological, Clinical, and Pathophysiological Aspects-Review of the Literature and Clinical Trials","volume":"23","author":"Surma","year":"2021","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0002-9343(96)80224-5","article-title":"Transmission and Epidemiology of Helicobacter Pylori","volume":"100","author":"Cave","year":"1996","journal-title":"Am. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global Prevalence of Helicobacter Pylori Infection: Systematic Review and Meta-Analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Fang, Y., Fan, C., Xie, H., and Bil, J. (2019). Effect of Helicobacter Pylori Infection on the Risk of Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Medecine, 98.","DOI":"10.1097\/MD.0000000000018348"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12761","DOI":"10.1111\/hel.12761","article-title":"A Meta-Analysis of the Association between Helicobacter Pylori Infection and Risk of Atherosclerotic Cardiovascular Disease","volume":"25","author":"Wang","year":"2020","journal-title":"Helicobacter"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.3748\/wjg.v24.i29.3204","article-title":"Helicobacter Pylori and Extragastric Diseases: A Review","volume":"24","author":"Gravina","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9882","DOI":"10.3748\/wjg.v20.i29.9882","article-title":"Structural Modifications of Helicobacter Pylori Lipopolysaccharide: An Idea for How to Live in Peace","volume":"20","author":"Chmiela","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sutanto, H., and Lyon, A. (2021). Predicting the Neuro-Cardio-Haemodynamic Outcomes of Sepsis and Its Pharmacological Interventions: Get to the Future through Numerical Equations. J. Physiol., 1\u20133.","DOI":"10.1113\/JP281661"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s10875-009-9333-5","article-title":"Autoimmunity, Infectious Immunity, and Atherosclerosis","volume":"29","author":"Matsuura","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcla.22222","article-title":"A Link between Platelet to Lymphocyte Ratio and Helicobacter Pylori Infection","volume":"32","author":"Farah","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jcla.21669","article-title":"Association of Neutrophil to Lymphocyte Ratio with Presence and Severity of Gastritis Due to Helicobacter Pylori Infection","volume":"28","author":"Farah","year":"2014","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S2468-1253(19)30227-4","article-title":"Global Burden of Atherosclerotic Cardiovascular Disease in People with Hepatitis C Virus Infection: A Systematic Review, Meta-Analysis, and Modelling Study","volume":"4","author":"Lee","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejim.2019.03.004","article-title":"Hepatitis C Virus Infection and Risk of Coronary Artery Disease: A Meta-Analysis","volume":"63","author":"Wen","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/clc.23299","article-title":"Inflammatory and Cardiovascular Diseases Biomarkers in Chronic Hepatitis C Virus Infection: A Review","volume":"43","author":"Babiker","year":"2020","journal-title":"Clin. Cardiol."},{"key":"ref_73","first-page":"58","article-title":"Prevalence and Association of HBV and HCV Infection with Cardiovascular Disease Risk Factors in a Peri-Urban Population","volume":"70","author":"Jabeen","year":"2020","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40121-017-0171-0","article-title":"Effect of Hepatitis C Treatment with Ombitasvir\/Paritaprevir\/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials","volume":"6","author":"Mehta","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2019.10.015","article-title":"Hepatitis C Virus (HCV) Infection and Cardiovascular Disease: Hepatologists and Cardiologists Need to Talk!","volume":"71","author":"Wernly","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_76","first-page":"1","article-title":"Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease","volume":"63","year":"2014","journal-title":"Physiol. Behav."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1128\/IAI.00007-16","article-title":"Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis Following Pneumococcal Myocardial Invasion","volume":"84","author":"Gilley","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1164\/rccm.201411-1951PP","article-title":"Cardiotoxicity during Invasive Pneumococcal Disease","volume":"191","author":"Brown","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/ATVBAHA.120.314645","article-title":"Role of Platelets in Detection and Regulation of Infection","volume":"41","author":"Portier","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00083","article-title":"The Inflammatory Role of Platelets via Their TLRs and Siglec Receptors","volume":"6","author":"Cognasse","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2014.07.985","article-title":"Platelet Activation Is Associated with Myocardial Infarction in Patients with Pneumonia","volume":"64","author":"Cangemi","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MCP.0000000000000261","article-title":"Cardiovascular Disease as a Complication of Community-Acquired Pneumonia","volume":"22","author":"Rae","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.008074","article-title":"Estimated Cardiac Risk Associated with Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities","volume":"7","author":"Polgreen","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijid.2020.07.038","article-title":"The Protective Effect of Pneumococcal Vaccination on Cardiovascular Disease in Adults: A Systematic Review and Meta-Analysis","volume":"99","author":"Marra","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.005025","article-title":"Cytomegalovirus Infection and Relative Risk of Cardiovascular Disease (Ischemic Heart Disease, Stroke, and Cardiovascular Death): A Meta-Analysis of Prospective Studies up to 2016","volume":"6","author":"Wang","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virusres.2016.09.010","article-title":"Human Cytomegalovirus Infection and Vascular Disease Risk: A Meta-Analysis","volume":"227","author":"Lv","year":"2017","journal-title":"Virus Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11904-016-0297-9","article-title":"Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection","volume":"13","author":"Freeman","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.003759","article-title":"Cytomegalovirus-Productive Infection Is Associated with Acute Coronary Syndrome","volume":"5","author":"Nikitskaya","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1160\/TH09-04-0213","article-title":"Endothelial Cells in Human Cytomegalovirus Infection: One Host Cell out of Many or a Crucial Target for Virus Spread?","volume":"102","author":"Adler","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/01.CIR.0000109692.16004.AF","article-title":"Cytomegalovirus Infection Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine in Transplant Arteriosclerosis","volume":"109","author":"Weis","year":"2004","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41371-020-0387-4","article-title":"Covid-19 and the Cardiovascular System: A Comprehensive Review","volume":"35","author":"Azevedo","year":"2021","journal-title":"J. Hum. Hypertens."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"110454","DOI":"10.1016\/j.mehy.2020.110454","article-title":"Correlation between Takotsubo Cardiomyopathy and SARS-CoV-2 Infection","volume":"146","author":"Szarpak","year":"2021","journal-title":"Med. Hypotheses"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10557-020-07084-9","article-title":"Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment","volume":"35","author":"Borovac","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"159","DOI":"10.31083\/j.rcm.2021.01.238","article-title":"Cardiovascular Complications of SARS-CoV-2 Infection (COVID-19): A Systematic Review and Meta-Analysis","volume":"22","author":"Zhao","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_95","first-page":"485","article-title":"Impaired Microcirculation Function in Covid-19 and Implications for Potential Therapies","volume":"27","author":"Filipiak","year":"2020","journal-title":"Cardiol. J."},{"key":"ref_96","first-page":"98","article-title":"Cytokines as Predictors of COVID-19 Severity: Evidence from a Meta-Analysis","volume":"131","author":"Szarpak","year":"2021","journal-title":"Polish Arch. Intern. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"886","DOI":"10.5603\/CJ.a2020.0171","article-title":"Evidence of Diagnostic Value of Ferritin in Patients with COVID-19","volume":"27","author":"Szarpak","year":"2020","journal-title":"Cardiol. J."},{"key":"ref_98","unstructured":"Hertanto, D.M., Sutanto, H., and Wungu, C.D.K. (2021). Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. Preprints."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/cvr\/cvaa230","article-title":"Endothelial Dysfunction in COVID-19: A Position Paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science","volume":"116","author":"Evans","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"217","DOI":"10.33963\/KP.15830","article-title":"D-Dimer Levels Predict COVID-19 Severity and Mortality","volume":"79","author":"Ruetzler","year":"2021","journal-title":"Kardiol. Pol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ajem.2020.04.048","article-title":"Cardiovascular complications in COVID-19","volume":"38","author":"Long","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5603\/CJ.a2021.0028","article-title":"Post-Covid-19 Heart Syndrome","volume":"28","author":"Gasecka","year":"2021","journal-title":"Cardiol. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"E279","DOI":"10.1016\/S2352-3018(20)30036-9","article-title":"HIV and Cardiovascular Disease","volume":"7","author":"Benjamin","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_106","first-page":"39","article-title":"Herpes Simplex Virus and Atherosclerosis","volume":"14","author":"Visser","year":"1993","journal-title":"Eur. Heart J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/ije\/dyl166","article-title":"Serum Antibody Response to Periodontal Pathogens and Herpes Simplex Virus in Relation to Classic Risk Factors of Cardiovascular Disease","volume":"35","author":"Pussinen","year":"2006","journal-title":"Int. J. Epidemiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.08.020","article-title":"Seropositivity to Herpes Simplex Virus Type 2, but Not Type 1 Is Associated with Premature Cardiovascular Diseases: A Population-Based Cross-Sectional Study","volume":"231","author":"Mendy","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1160\/TH11-06-0392","article-title":"Pathogens and Atherosclerosis: Update on the Potential Contribution of Multiple Infectious Organisms to the Pathogenesis of Atherosclerosis","volume":"106","author":"Rosenfeld","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1093\/eurheartj\/ehx362","article-title":"Infections, Atherosclerosis, and Coronary Heart Disease","volume":"38","author":"Pothineni","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-Reactive Protein and LDL Cholesterol and Cardiovascular Event Rates after Initiation of Rosuvastatin: A Prospective Study of the JUPITER Trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","article-title":"Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model","volume":"35","author":"Thomas","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events after Acute Myocardial Infarction: An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"McMurray","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour Necrosis Factor Antagonist Use and Associated Risk Reduction of Cardiovascular Events among Patients with Rheumatoid Arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/bph.13818","article-title":"Targeting Inflammation to Reduce Cardiovascular Disease Risk: A Realistic Clinical Prospect?","volume":"174","author":"Welsh","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual Inflammatory Risk on Treatment with PCSK9 Inhibition and Statin Therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 Inhibition and Inflammation: A Narrative Review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cmi.2018.11.003","article-title":"Hydroxymethylglutaryl-CoA Reductase Inhibitors (Statins) for the Treatment of Sepsis in Adults\u2014A Systematic Review and Meta-Analysis","volume":"25","author":"Pertzov","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11239-017-1516-y","article-title":"Platelet-Related Biomarkers and Their Response to Inhibition with Aspirin and P2y12-Receptor Antagonists in Patients with Acute Coronary Syndrome","volume":"44","author":"Lowenstern","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/clc.20732","article-title":"Changes in Inflammatory Biomarkers in Patients Treated with Ticagrelor or Clopidogrel","volume":"33","author":"Husted","year":"2010","journal-title":"Clin. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1160\/TH16-10-0799","article-title":"A Randomized Trial on the Effect of Anti-Platelet Therapy on the Systemic Inflammatory Response in Human Endotoxemia","volume":"117","author":"Kiers","year":"2017","journal-title":"Thrombo. Haemost."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jth.14689","article-title":"Ticagrelor Attenuates the Increase of Extracellular Vesicle Concentrations in Plasma after Acute Myocardial Infarction Compared to Clopidogrel","volume":"18","author":"Gasecka","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"G\u0105secka, A., Rogula, S., Eyileten, C., Postu\u0142a, M., Jaguszewski, M.J., Kochman, J., Mazurek, T., Nieuwland, R., and Filipiak, K.J. (2020). Role of P2y Receptors in Platelet Extracellular Vesicle Release. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176065"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2012.08.018","article-title":"Angiotensin Converting Enzyme 2 and Atherosclerosis","volume":"226","author":"Wang","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jcp.27205","article-title":"The Potential Therapeutic Use of Renin\u2013Angiotensin System Inhibitors in the Treatment of Inflammatory Diseases","volume":"234","author":"Ranjbar","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00392-005-0222-5","article-title":"Influence of the Angiotensin Converting Enzyme Inhibitor Ramipril on High-Sensitivity C-Reactive Protein (Hs-CRP) in Patients with Documented Atherosclerosis","volume":"94","author":"Mitrovic","year":"2005","journal-title":"Z. Kardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2008.08.042","article-title":"ACE Inhibition with Perindopril and Biomarkers of Atherosclerosis and Thrombosis: Results from the PERTINENT Study","volume":"204","author":"Ceconi","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijcard.2011.01.030","article-title":"Rosuvastatin Combined with Ramipril Significantly Reduced Atheroma Volume by Anti-Inflammatory Mechanism: Comparative Analysis with Rosuvastatin Alone by Intravascular Ultrasound","volume":"158","author":"Han","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e002128","DOI":"10.1161\/JAHA.115.002128","article-title":"Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients with an Acute Coronary Syndrome","volume":"4","author":"Robertson","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcard.2019.01.054","article-title":"ichiro. Effect of Short-Term Colchicine Treatment on Endothelial Function in Patients with Coronary Artery Disease","volume":"281","author":"Kajikawa","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.clinthera.2019.07.015","article-title":"Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients with an Acute Coronary Syndrome: A Pilot Study","volume":"41","author":"Tucker","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinthera.2018.09.011","article-title":"Colchicine in Stable Coronary Artery Disease","volume":"41","author":"Fiolet","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1060028020942144","article-title":"Colchicine in Acute Coronary Syndrome: A Systematic Review","volume":"55","author":"McKnight","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting Inflammation in Coronary Artery Disease","volume":"377","author":"Harrington","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/12\/2539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:12:01Z","timestamp":1760163121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/12\/2539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":139,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jcm10122539"],"URL":"https:\/\/doi.org\/10.3390\/jcm10122539","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]}}}